Psyence Group (CSE:PSYG) provides corporate update

Psyence Group (PSYG) has provided an update on its three strategic focus areas
Dr. Clive Ward-Able has been appointed as Medical Director, Head of Research & Development and Early Commercialization
ISO22000 certified commercial psilocybin production facility and lab upgraded
GOODMIND™, functional mushroom product, launched online and in-store
The company completed a C$1.273 million private placement

Psyence Group (PSYG) has provided an update on its three strategic focus areas namely: Psyence Therapeutics, Psyence Production and Psyence Function.

Highlights:

Partnership with CRO Clerkenwell Health to design and deliver Psyence’s UK clinical trial progressing; exclusive licensing agreement with Filament Health
Dr. Clive Ward-Able has been appointed as Medical Director, Head of Research & Development and Early Commercialization for Psyence
ISO22000 certified commercial psilocybin production facility and lab upgraded
Received an import permit from Health Canada on behalf of Psilo Scientific
GOODMIND™, functional mushroom product, launched online and in-store, sale through 300 stores of one of Africa’s largest coffee retail chains
Previously announced C$1.273 million private placement being closed
Exploring capital market initiatives in UK, hires Investment Bank

Psyence CEO Dr. Neil Maresky, sat down with Coreena Robertson to discuss the update.

Psyence is a life science biotechnology company focused on natural psychedelics. Psyence works with natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care.

Psysence Group Inc. (PSYG) opened trading at C$0.085 per share.